15793S2303-NCT06203600OpenRandomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMMUNE)
S2303NCT06203600NationalAdultTreatmentII/IIIOtherNoel, MarcusGeorgetown University Medical Center : Princess Jones; Lombardi Comprehensive Cancer Center : Princess JonesGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC)- 14509Princess JonesPrincess Jonespaj24@georgetown.edu
2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>